Substituted 6-aminoquinoline-3-carbonitrile, 19 | 915363-35-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: Substituted 6-aminoquinoline-3-carbonitrile, 19
• 英文别名: 8-bromo-4-(3-chloro-4-fluoroanilino)-6-[[1-(pyridin-3-ylmethyl)triazol-4-yl]methylamino]quinoline-3-carbonitrile
• CAS: 915363-35-8
• 化学式: C₂₅H₁₇BrClFN₈
• 分子量: 563.819
• InChiKey: NDZILMRCELWAKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  6-amino-8-bromo-4-((3-chloro-4-fluorophenyl)amino)quinoline-3-carbonitrile 、 1-(pyridin-3-ylmethyl)-1H-1,2,3-triazole-4-carbaldehyde 在 三乙酰氧基硼氢化钠 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 4.0h， 生成 Substituted 6-aminoquinoline-3-carbonitrile, 19
  参考文献：
  名称：

  Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-α production in human whole blood

  摘要：

  Tpl2 (cot/MAP3K8) is an upstream kinase of MEK in the ERK pathway. It plays an important role in Tumor Necrosis Factor-alpha (TNF-alpha) production and signaling. We have discovered that 8-halo-4-(3-chloro-4-fluorophenylamino)-6-[(1H-[ 1,2,3]triazol-4-ylmethyl)-amino]-quinoline-3-carbonitriles (4) are potent inhibitors of this enzyme. In order to improve the inhibition of TNF-alpha production in LPS-stimulated human blood, a series of analogs with a variety of substitutions around the triazole moiety were studied. We found that a cyclic amine group appended to the triazole ring could considerably enhance potency, aqueous solubility, and cell membrane permeability. Optimization of these cyclic amine groups led to the identification of 8-chloro-4-(3-chloro-4-fluorophenylamino)-6-((1-(1-ethylpiperidin-4-yl)-1H-1,2,3-triazol- 4-yl) methylamino)quinoline-3-carbonitrile (34). In a LPS-stimulated rat inflammation model, compound 34 showed good efficacy in inhibiting TNF-alpha production. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.05.009

文献信息

• 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same
  申请人：Green Jeffrey Neal

  公开号：US20060264460A1

  公开（公告）日：2006-11-23

  The present invention provides compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , m and n are defined as described herein. The invention also provides methods of making the compounds of formula (I), and methods of treating inflammatory diseases, such as rheumatoid arthritis, in a mammal comprising administering a therapeutically effective amount of a compound of formula (I) to the mammal.

  本发明提供了如下式（I）的化合物及其药用可接受的盐，其中R1、R2、R3、R4、R5、R6、R7、R8、m和n的定义如本文所述。该发明还提供了制备如式（I）化合物的方法，以及治疗炎症性疾病（如类风湿性关节炎）的方法，包括向哺乳动物施用如式（I）化合物的治疗有效量。
• 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME
  申请人：Wyeth

  公开号：EP1888529A2

  公开（公告）日：2008-02-20
• [EN] 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME<br/>[FR] INHIBITEURS 3-CYANOQUINOLINE DE LA TPL2 KINASE ET PROCEDES DE PRODUCTION ET D'UTILISATION ASSOCIES
  申请人：WYETH CORP

  公开号：WO2006124692A2

  公开（公告）日：2006-11-23

  [EN] The present invention provides compounds of formula (I): CHEMICAL FORMULA SHOULD BE INSERTED HERE AS IT APPEARS ON THE ABSTRACT IN PAPER FORM. (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, m and n are defined as described herein. The invention also provides methods of making the compounds of formula (I), and methods of treating inflammatory diseases, such as rheumatoid arthritis, in a mammal comprising administering a therapeutically effective amount of a compound of formula (I) to the mammal.
  [FR] L'invention concerne des composés de formule (I): (I), et des sels pharmaceutiquement acceptables de ces composés, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, m et n étant comme définis dans la description. La présente invention porte également sur des procédés pour produire des composés de formule (I), et sur des méthodes pour traiter des maladies inflammatoires telles que la polyarthrite rhumatoïde chez un mammifère, par administration d'une quantité thérapeutiquement suffisante d'un composé de formule (I) au mammifère.
• Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-α production in human whole blood
  作者：Junjun Wu、Neal Green、Rajeev Hotchandani、Yonghan Hu、Jeffrey Condon、Adrian Huang、Neelu Kaila、Huan-Qiu Li、Satenig Guler、Wei Li、Steve Y. Tam、Qin Wang、Jeffrey Pelker、Suzana Marusic、Sang Hsu、J. Perry Hall、Jean-Baptiste Telliez、Junqing Cui、Lih-Ling Lin

  DOI：10.1016/j.bmcl.2009.05.009

  日期：2009.7

  Tpl2 (cot/MAP3K8) is an upstream kinase of MEK in the ERK pathway. It plays an important role in Tumor Necrosis Factor-alpha (TNF-alpha) production and signaling. We have discovered that 8-halo-4-(3-chloro-4-fluorophenylamino)-6-[(1H-[ 1,2,3]triazol-4-ylmethyl)-amino]-quinoline-3-carbonitriles (4) are potent inhibitors of this enzyme. In order to improve the inhibition of TNF-alpha production in LPS-stimulated human blood, a series of analogs with a variety of substitutions around the triazole moiety were studied. We found that a cyclic amine group appended to the triazole ring could considerably enhance potency, aqueous solubility, and cell membrane permeability. Optimization of these cyclic amine groups led to the identification of 8-chloro-4-(3-chloro-4-fluorophenylamino)-6-((1-(1-ethylpiperidin-4-yl)-1H-1,2,3-triazol- 4-yl) methylamino)quinoline-3-carbonitrile (34). In a LPS-stimulated rat inflammation model, compound 34 showed good efficacy in inhibiting TNF-alpha production. (C) 2009 Elsevier Ltd. All rights reserved.